United Therapeutics
Clinical trials sponsored by United Therapeutics, explained in plain language.
Develops therapies for pulmonary arterial hypertension and other chronic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for PAH patients: Long-Term drug safety trial opens Results expected Dec 2026 (estimated) May already have reported ↗
- New registry follows PAH patients on orenitram in Real-World settings Results expected Mar 2027 (estimated)
-
New PAH pill aims to delay worsening in large trial
Disease control CompletedThis study tested a new oral drug called ralinepag in 687 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work harder. Participants took ralinepag or a placebo on top of their usual PAH medications. The main goal was to see if rali…
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Inhaled treprostinil aims to slow IPF lung damage in major trial
Disease control CompletedThis Phase 3 trial tested whether an inhaled drug called treprostinil (Tyvaso) could slow the loss of lung function in 598 adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. Participants inhaled the drug or a placebo four times daily for 52 weeks. The ma…
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New screening method could catch hidden lung complication early
Knowledge-focused CompletedThis study looked at ways to screen for pulmonary hypertension (high blood pressure in the lungs) in people who already have interstitial lung disease. The goal was to find this complication earlier. 314 adults with various types of lung disease took part in the screening tests.
Sponsor: United Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC